Positive results from the AEGEAN Phase III trial showed that treatment with AstraZeneca’s IMFINZI in combination with neoadjuvant chemotherapy before surgery and as adjuvant monotherapy...
G42 Healthcare, an Abu Dhabi-based leading health tech company and subsidiary of G42, an artificial intelligence and cloud computing company located in Abu Dhabi...
BenevolentAI, a leading clinical-stage AI-enabled drug discovery company, announces that AstraZeneca has selected an additional novel target for idiopathic pulmonary fibrosis (IPF) for its...
Harbour BioMed, a global biopharmaceutical company committed to the discovery, development, and commercialization of novel antibody therapeutics, announced a global out-license agreement with AstraZeneca...
